Vergoeding 2015-2019 voor ATC-subgroep V03AE : Middelen bij hyperkaliemie en hyperfosfatemie
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| V03AE01 Polystyreensulfonzuur (na-zout ca-zout) (Resonium a ®) | 1.638.700 | 1.643.400 | 1.689.600 | 1.692.700 | 1.635.200 |
| V03AE02 Sevelameer (Renagel ®) | 9.700.400 | 6.714.100 | 4.922.400 | 3.691.700 | 2.951.900 |
| V03AE03 Lanthaancarbonaat (Fosrenol ®) | 3.105.200 | 3.320.100 | 3.337.200 | 3.275.300 | 3.640.500 |
| V03AE04 Calciumacetaat met magnesiumcarbonaat (Osvaren ®) | 71.803 | 66.492 | 62.895 | 58.631 | 76.914 |
| V03AE05 Ferrioxyhydroxide-sucrose-complex (Velphoro ®) | 86.331 | 236.090 | 402.130 | 564.900 | 588.660 |
| V03AE07 Calciumacetaat (Calciumacetaat nefro ®) | 100 | . | . | . | 279 |
| V03AE09 Patiromeer calcium (Veltassa ®) | . | . | . | . | 15.967 |
| Totaal | 14.602.534 | 11.980.182 | 10.414.225 | 9.283.231 | 8.909.420 |